Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Pyxis Oncology Inc (NASDAQ: PYXS) closed at $1.20 in the last session, down -1.64% from day before closing price of $1.22. In other words, the price has decreased by -$1.64 from its previous closing price. On the day, 0.51 million shares were traded.
Ratios:
We take a closer look at PYXS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.33 and its Current Ratio is at 7.33. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
On November 08, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $13.
On August 08, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $10.Stifel initiated its Buy rating on August 08, 2024, with a $10 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 26 ’24 when Connealy Pamela Ann bought 88,850 shares for $1.96 per share. The transaction valued at 174,364 led to the insider holds 1,199,143 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.42 while its Price-to-Book (P/B) ratio in mrq is 0.46.
Stock Price History:
Over the past 52 weeks, PYXS has reached a high of $6.85, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is -20.75%, while the 200-Day Moving Average is calculated to be -59.89%.
Shares Statistics:
A total of 59.45M shares are outstanding, with a floating share count of 42.26M. Insiders hold about 28.94% of the company’s shares, while institutions hold 40.70% stake in the company.
